Finerenone Prescriptions in the United States (2021–2024) by Physician Specialty: Analysis of Use and Potential in the Cardiovascular‐Kidney‐Metabolic Space
Yara Jelwan, Tianyu Cao, Zhiqi Yao, Semenawit Burka, John Erhabor, Phillip Berning, Omar Dzaye, Michael Blaha · 2026
Read Finerenone Prescriptions in the United States (2021–2024) by Physician Specialty: Analysis of Use and Potential in the Cardiovascular‐Kidney‐Metabolic Space by Yara Jelwan, Tianyu Cao, Zhiqi Yao, Semenawit Burka, John Erhabor, Phillip Berning, Omar Dzaye, Michael Blaha (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13323811.txt.
Description
Yara Jelwan and co-authors tracked how finerenone, a newer mineralocorticoid receptor blocker, is being used in the United States. Their 2026 serial cross-sectional study used IQVIA drug-sales audit data covering more than 70% of outpatient use, from July 2021 through December 2024, focusing on cardiologists and nephrologists. Trials support the drug for kidney progression, cardiovascular events, and heart failure, yet anecdote suggested it was rarely used.
Uptake proved modest: sales crept upward, with mild jumps after major trial releases that also tracked with search interest, but the drug still equaled only 3.0% of empagliflozin sales and 2.6% of spironolactone sales in 2024. The specialty gap was stark, at about 23 orders per kidney doctor for every 0.70 per cardiologist. The authors see a slow shift upward, led by kidney specialists, with cardiology adoption lagging well behind.
Catalog record
| CREATOR | Yara Jelwan, Tianyu Cao, Zhiqi Yao, Semenawit Burka, John Erhabor, Phillip Berning, Omar Dzaye, Michael Blaha |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |